DGAP-News: Teladoc & Cloud DX Go Global With Connected Health 15.09.2022, 14:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse

DGAP-News: Cloud DX, Inc.
Teladoc & Cloud DX Go Global With Connected Health

15.09.2022 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Telehealth has seemingly changed the healthcare landscape, providing individuals with access to health services wherever they are without the need to travel.

Telehealth, sometimes referred to as telemedicine, is the integration of telecommunication systems into the practice of protecting health, done primarily online with internet access via a computer, tablet or smartphone.

The COVID-19 pandemic saw explosive growth of telehealth — skyrocketing to a historic peak in April 2020, as both consumers and healthcare providers sought ways to safely access and deliver healthcare. Its use began trending down towards the end of 2020, ticking back up in October 2020 and stabilizing in 2021 to 38X higher than pre-COVID-19 usage, according to McKinsey & Company.

Telehealth Is Here To Stay

Supportive regulations seem to have accelerated telehealth use. By all counts, telehealth seems to be here to stay — the telehealth market is projected to grow from $90.74 billion in 2021 to $636.38 billion in 2028 at a compound annual growth rate (CAGR) of 32.1% in the forecast period, 2021 to 2028.

Cloud DX (TSXV: CDX) (OTC: CDXFF), a Canada-based digital health platform and RPM solution provider, announced on Aug. 26, 2022, its new strategic partnership with telemed company Teladoc Health Inc. (NYSE: TDOC) to enhance remote monitoring solutions for patients across Canada.

The partnership will see Teladoc Health offerings available on Cloud DX’s Clinician Portal and patient facing app, Connected Health™, via integration on the Cloud DX platform. The platform lets partners, like Teladoc, leverage Cloud DX’s infrastructure, including Electronic Medical Record (EMR) integration, support services, and patient apps — some of the biggest hurdles to overcome in health tech adoption. Approved partners connect their software or hardware tools via an API, enabling patients to use their offerings and securely transmit data to their care team in the Clinician Portal. Offerings such as Teladoc’s Livongo diabetes devices, Solo™ virtual care solution, vital devices like pulse oximeters, or curated health content - all easily available in the Connected Health™ app.

Delivering Teladoc offerings via the Cloud DX platform means any Cloud DX client can easily add on Teladoc offerings. The two-way partnership also lets Canadian Teladoc clients opt to have services delivered through Cloud DX’s Connected Health™ solution.

The data gathered through its Connected Health platform supports providers managing acute and chronic diseases, including people with COPD, heart failure or post-surgical needs — enabling better healthcare and patient outcomes and reducing hospitalizations or re-admissions. Teladoc reportedly has global expertise in chronic care management in the community and offers its Solo™ virtual care software platform for use in more than 4,000 hospitals and health systems worldwide, including in Canada.

According to Cloud DX, its partnership with Teladoc enables the use of Solo™ on its patient app experience in Canada. This expands Cloud DX’s virtual care partner offerings to include Solo™ and Microsoft Teams, in addition to Zoom. Cloud DX patients or users now have more options to easily and seamlessly connect with members of their clinical team and Cloud DX clients can choose to use Solo™ as its virtual care option, or other available Cloud DX partner solutions.

Commenting on the partnership, Robert Kaul, CEO and founder of Cloud DX, said: "We are very pleased to welcome Teladoc Health as a fully integrated partner on the Cloud DX platform in Canada. From its leading virtual care solution, Solo™, to its chronic care management and mental health programs, offering Teladoc Health services as part of the Connected Health™ ecosystem creates a compelling and robust remote patient monitoring solution. Together, Teladoc Health and Cloud DX offer a complete, best-in-class tool kit for healthcare providers to address acute and complex cases. As partners, we look forward to creating better healthcare journeys for more Canadians."

Cloud DX is also an exclusive partner to Medtronic Canada and Equitable Life of Canada.

To learn more about Cloud Dx and its products visit www.clouddx.com.

Cloud DX Inc. is a leading competitor in the highly regulated digital healthcare industry. We provide remote patient monitoring hardware, software and recurring revenue services in a frictionless, reimbursable transaction model, coupled with a sales strategy that's driving rapid adoption among global healthcare providers.Our Cloud DX Connected Health products were invented and developed in Toronto Canada and Team Cloud DX is Canada’s entry in the Qualcomm Tricorder XPRIZE. Our US headquarters is in Brooklyn NY.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Jay Bedard, IR Manager

jay.bedard@clouddx.com

Company Website

https://www.clouddx.com/#/


News Source: News Direct


15.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Cloud DX, Inc.
United States
ISIN: CA18912D1006
EQS News ID: 1443595

 
End of News DGAP News Service

1443595  15.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1443595&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer